Standard BioTools Inc
LAB
Market Cap$956.4M
Close$
Share Statistics
| Market cap | $956.40 Million |
|---|---|
| Enterprise Value | $549.08 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.02 |
| Beta | 1.16 |
| Outstanding Shares | 372,141,530 |
| Avg 30 Day Volume | 2,734,094 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.03 |
|---|---|
| PEG | -1.93 |
| Price to Sales | - |
| Price to Book Ratio | 2.57 |
| Enterprise Value to Revenue | 4.33 |
| Enterprise Value to EBIT | -6.45 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
ESG Score
No data
About Standard BioTools Inc
627 employees
CEO: Stephen Linthwaite Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-om...